Live Analysis: Agilent Technologies, Inc. (A) is currently priced at $115, showing a decrease of 62 cents (-0.536%) from the previous close of $115.62. With a trading volume of $442,608, which is 19.89% above the average, the stock is experiencing notable movement.
Earnings Overview: Agilent's latest quarterly earnings report, announced on Tuesday, February 24th, revealed a consensus estimate EPS of 1.37.
Dividends: The company offers a forward dividend yield of 0.887% with a dividend per share MRQ of 25.5 cents, showing a year-over-year increase of 4.4979 cents.
Cash Flow: Agilent's free cash flow stands at $175 million, with operating cash flow at $268 million. Notably, the company repurchased $152 million worth of common stock.
Income Statement: Agilent reported a revenue of $1.80 billion, generating a gross profit of $946 million. The net income for the period was $305 million, resulting in an EPS of $1.08.
Ratios: Key ratios include a net profit margin of 16.96%, return on assets of 2.38%, and a price-to-earnings ratio of 31.05.
Balance Sheet: Agilent's total assets amount to $12.81 billion, with total liabilities at $5.91 billion, indicating a strong financial position.
This comprehensive analysis provides insights into Agilent Technologies, Inc.'s financial performance and market behavior, guiding investors in understanding the current state of the asset.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.